<DOC>
	<DOCNO>NCT02685631</DOCNO>
	<brief_summary>This research registry study Yttrium Y 90 resin microspheres collect data patient liver cancer capable remove surgery ( unresectable ) radiation-emitting Selective Internal Radiation-Spheres ( SIR-spheres ) non-resectable ( RESIN ) liver tumor registry . The information generate help doctor well understand treatment pattern involve Y90 therapy , gain additional insight long-term outcome patient , well guide future research use Y90 therapy , especially condition data currently limit lacking .</brief_summary>
	<brief_title>Yttrium Y 90 Resin Microspheres Data Collection Unresectable Liver Cancer : RESIN Study</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . The principal objective RESIN registry evaluate response therapy use objective response criterion modify Response Evaluation Criteria Solid Tumors ( mRECIST ) European Association Study Liver ( EASL ) . The response criterion use depend tumor type treat local policy registry formal research study . Secondary criterion include overall survival , time progression ( TTP ) toxicity . OUTLINE : Patients receive Yttrium Y90 resin microspheres treatment part overall oncologic management add RESIN registry database collect document information include : patient demographic ( gender/age ) , previous oncologic treatment , detail Yttrium Y90 resin microspheres treatment , track outcome complication .</detailed_description>
	<mesh_term>Carcinoma , Hepatocellular</mesh_term>
	<criteria>Patients receive SIRSpheres therapy liver first time . Provision write informed consent . Age 18 old . 1 . Prior completion Y90 therapy liver ( SIRSpheres , TheraSpheres , livertargeted therapy involve use radiationemitting sphere ) . Patients receive Y90 treatment past return another Y90 treatment ineligible , even new area target . 2 . Need surrogate consent . Patients unable consent behalf eligible study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Hepatocellular carcinoma</keyword>
	<keyword>Colorectal cancer</keyword>
	<keyword>Neuroendocrine tumor</keyword>
	<keyword>Cholangiocarcinoma</keyword>
	<keyword>Breast cancer</keyword>
	<keyword>Tumor unknown primary</keyword>
	<keyword>Pancreatic cancer</keyword>
</DOC>